ベバシズマブバイオシミラーの世界市場レポート 2024

ベバシズマブバイオシミラーの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.8%の年間複合成長率（CAGR）で20億9,000万米ドルに成長すると予想されます。予測される成長は、がん治療薬、バイオシミラー開発の専門知識、ヘルスケアシステムの圧力、進化するバイオシミラー規制、および互換性の考慮に対する需要の増加によって促進されます。主な動向には、コラボレーション、規制の進歩、進行中のバイオシミラー開発、市場アクセス戦略、効果的なライフサイクル管理が含まれます。

がん罹患率の予想される増加は、将来のベバシズマブバイオシミラー市場の成長を促進する態勢が整っています。がんの発生率は、一定期間内の特定の集団内での新たながん症例の数を表し、この増加に寄与する重要な要因です。生物学的製剤であるベバシズマブは、腫瘍の血管新生を阻害することで機能し、腫瘍の縮小と増殖の阻害を引き起こします。特に進行性非小細胞肺がんや転移性結腸直腸がん患者の治療において、参考生物製剤に匹敵する有効性と安全性が実証されています。たとえば、2022年10月の時点で、英国に拠点を置くヘルスケア慈善団体であるマクミラン・キャンサー・サポートの報告書では、がん患者は2020年の300万人から2025年までに350万人、2030年までに400万人、2040年までに530万人に増加すると予想されています。したがって、がんの有病率の上昇は、ベバシズマブバイオシミラー市場の重要な推進力となります。

予想されるヘルスケア支出の増加により、ベバシズマブバイオシミラー市場の拡大が促進される見込みです。特定の期間内のヘルスケア製品およびサービスに対する総金銭的支出を表すヘルスケア支出は、市場の成長に影響を与える極めて重要な要素です。 ベバシズマブバイオシミラーは、元の薬に代わる費用対効果の高い代替品を提供することで、ヘルスケア費の動向を形作る上で重要な役割を果たします。たとえば、2023年 3月、米国医師協会は、2021年の米国のヘルスケア支出は2.7%増加して4兆3,000億米ドル、一人当たり12,914ドルに達したと報告しました。特に、2009年から2019年の間、医師支出は年平均3.8%の増加を示しましたが、病院サービス（4.5%）と臨床サービス（6.6%）はより高い増加率を示しました。その結果、ヘルスケア費の急増はベバシズマブバイオシミラー市場の成長の触媒として機能します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のベバシズマブバイオシミラー市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• アバスチン
• ムヴァシ
• ジラベフ
• アイビンティオ
• その他の製品
• 世界のベバシズマブバイオシミラー市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• オンライン薬局
• 小売薬局
• その他の流通チャネル
• 世界のベバシズマブバイオシミラー市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 結腸直腸がん
• 非小細胞肺がん
• 膠芽腫
• 腎細胞がん
• 子宮頸がん
• 卵巣がん

第7章 地域および国の分析

• 世界のベバシズマブバイオシミラー市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のベバシズマブバイオシミラー市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ベバシズマブバイオシミラー市場の競合情勢
• ベバシズマブバイオシミラー市場企業プロファイル
  • Cipla Limited
  • Reliance lifesciences Pvt. Ltd.
  • Genentech Inc
  • Fujifilm Kyowa Kirin Biologics Co. Ltd.
  • Pfizer Inc.

第31章 その他の大手および革新的な企業

• AbbVie Inc.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Mylan Inc.
• Daiichi Sankyo Company Limited
• Beaconpharma Ltd.
• Innovent Biologics Inc.
• STADA Arzneimittel AG
• Shanghai Henlius Biotech Inc.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.
• Biocon Ltd.
• Intas Pharmaceuticals Ltd.
• Amneal Pharmaceuticals LLC

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Bevacizumab biosimilars are a specific class of medications that closely resemble a reference biologic drug named bevacizumab. These biosimilars are designed to mimic the original drug's properties and are frequently utilized to impede the formation of new blood vessels within tumors. By inhibiting this process, they effectively decelerate the progression of tumors.

Bevacizumab biosimilar products, including Avastin, Mvasi, Zirabev, Aybintio, and similar alternatives, represent a range of anti-angiogenic therapies designed to impede new blood vessel formation. These products are accessible through diverse distribution channels such as hospital pharmacies, online platforms, and retail outlets. Their applications span across treating colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.

The bevacizumab biosimilar market research report is one of a series of new reports from The Business Research Company that provides bevacizumab biosimilar market statistics, including bevacizumab biosimilar industry global market size, regional shares, competitors with a bevacizumab biosimilar market share, detailed bevacizumab biosimilar market segments, market trends, and opportunities, and any further data you may need to thrive in the bevacizumab biosimilar industry. This bevacizumab biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bevacizumab biosimilars market size has grown strongly in recent years. It will grow from $1.43 billion in 2023 to $1.55 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. Historical growth can be attributed to patent expirations, cost containment efforts in healthcare, rising cancer rates, market competitiveness, patient access and affordability, and the increasing acceptance of biosimilars.

The bevacizumab biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. Forecasted growth is driven by increased demand for cancer therapies, biosimilar development expertise, healthcare system pressures, evolving biosimilar regulations, and considerations of interchangeability. Major trends include collaborations, regulatory advancements, ongoing biosimilar development, market access strategies, and effective lifecycle management.

The anticipated increase in the prevalence of cancer cases is poised to drive the growth of the bevacizumab biosimilars market in the future. Cancer incidence, representing the number of new cancer cases within a specific population during a defined period, is a key factor contributing to this growth. Bevacizumab, a biologic, functions by inhibiting tumor angiogenesis, leading to tumor shrinkage and growth inhibition. It has demonstrated efficacy and safety comparable to reference biologics, particularly in treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For instance, as of October 2022, reports from Macmillan Cancer Support, a UK-based healthcare charity organization, indicated an anticipated increase in cancer patients from 3 million in 2020 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer cases is a significant driver for the bevacizumab biosimilars market.

The anticipated growth in healthcare expenditure is poised to drive the expansion of the bevacizumab biosimilars market. Healthcare expenditure, representing the total monetary outlay on healthcare goods and services within a specific period, is a pivotal factor influencing market growth. The bevacizumab biosimilars play a crucial role in shaping healthcare expenditure dynamics by providing cost-effective alternatives to the original drug. For example, in March 2023, the American Medical Association reported that in 2021, healthcare spending in the United States increased by 2.7% to $4.3 trillion, amounting to $12,914 per capita. Notably, between 2009 and 2019, physician spending showed an average yearly increase of 3.8%, while hospital services (4.5%) and clinical services (6.6%) experienced higher growth rates. Consequently, the upsurge in healthcare expenditure acts as a catalyst for the growth of the bevacizumab biosimilars market.

Product innovation has become a prominent trend gaining traction in the bevacizumab biosimilars market. Key market players are strategically focusing on the development of inventive products to enhance their market positions. An illustrative example is the collaborative effort of Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, in May 2022, resulting in the launch of a biosimilar named Abevmy (bevacizumab). This biosimilar is designed to mirror Roche's Avastin (bevacizumab) and has received approval from Health Canada for application in four oncology indications. Abevmy boasts efficacy, safety, and quality comparable to the reference biologic, as it is a synthesized humanized monoclonal antibody (MA) that binds to and neutralizes the biologic action of human vascular endothelial growth factor (VEGF). This exemplifies the trend of product innovation as a strategic focus within the bevacizumab biosimilars market.

Leading companies in the bevacizumab biosimilars market are strategically engaging in collaborations to develop Next-Generation Biosimilars, a move aimed at fortifying and sustaining their market positions. Next-generation biosimilars contribute to the advancement of the bevacizumab biosimilars market through technological enhancements, improved manufacturing processes, and heightened therapeutic efficacy. A noteworthy example is the exclusive partnership formed in May 2022 between Prestige Biopharma, a Singapore-based pharmaceutical company, and Intas Pharmaceuticals, a multinational pharmaceutical company based in India. This collaboration focuses on Prestige's bevacizumab biosimilar, HD204, currently in Phase III development and designed to replicate Roche's Avastin for various cancers. The exclusive agreement covers key regions such as the US, Europe, and parts of Asia and Africa. With HD204 positioned to offer advancements in bevacizumab biosimilar technology, the collaboration allows Intas Pharmaceuticals to commercialize the biosimilar, leveraging its robust sales and marketing capabilities. This strategic alignment supports Prestige's broader goal of expanding market reach and providing affordable access to patients through its innovative bevacizumab production technology.

In November 2022, Biocon Biologics Ltd., an India-based firm and subsidiary of Biocon Ltd. engaged in the manufacturing of biopharmaceuticals, successfully acquired Viatris Inc.'s global biosimilars business for an undisclosed amount. This strategic acquisition is geared towards reinforcing Biocon Biologics' presence in the biosimilars market. Viatris Inc., based in the US, is a pharmaceutical and healthcare company specializing in medicines for major therapeutic areas, including cancer, with notable products such as Bevacizumab.

Major companies operating in the bevacizumab biosimilars market report are Cipla Limited, Reliance lifesciences Pvt. Ltd., Genentech Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., Abbvie Inc., Amgen Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., EirGen Pharma Ltd., Allergan Plc., Apotex Inc., BioXpress Therapeutics SA, Celgene Corporation Co. Ltd., mAbxience SA

North America was the largest region in the bevacizumab biosimilars market in 2023. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bevacizumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bevacizumab biosimilars market consists of sales of byvasda, cizumab, alymsys, bevax, and cyramza. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bevacizumab Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bevacizumab biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bevacizumab biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bevacizumab biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Product: Avastin; Mvasi; Zirabev; Aybintio; Other Products
• 2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
• 3) By Application: Colorectal Cancer; Non-small Cell Lung Cancer; Glioblastoma; Renal Cell Carcinoma; Cervical Cancer; Ovarian Cancer
• Companies Mentioned: Cipla Limited; Reliance lifesciences Pvt. Ltd.; Genentech Inc; Fujifilm Kyowa Kirin Biologics Co. Ltd.; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bevacizumab Biosimilars Market Characteristics

3. Bevacizumab Biosimilars Market Trends And Strategies

4. Bevacizumab Biosimilars Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Bevacizumab Biosimilars Market Size and Growth

• 5.1. Global Bevacizumab Biosimilars Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Bevacizumab Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Bevacizumab Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Bevacizumab Biosimilars Market Segmentation

• 6.1. Global Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Avastin
• Mvasi
• Zirabev
• Aybintio
• Other Products
• 6.2. Global Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.3. Global Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Glioblastoma
• Renal Cell Carcinoma
• Cervical Cancer
• Ovarian Cancer

7. Bevacizumab Biosimilars Market Regional And Country Analysis

• 7.1. Global Bevacizumab Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Bevacizumab Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Bevacizumab Biosimilars Market

• 8.1. Asia-Pacific Bevacizumab Biosimilars Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Bevacizumab Biosimilars Market

• 9.1. China Bevacizumab Biosimilars Market Overview
• 9.2. China Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Bevacizumab Biosimilars Market

• 10.1. India Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Bevacizumab Biosimilars Market

• 11.1. Japan Bevacizumab Biosimilars Market Overview
• 11.2. Japan Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Bevacizumab Biosimilars Market

• 12.1. Australia Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Bevacizumab Biosimilars Market

• 13.1. Indonesia Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Bevacizumab Biosimilars Market

• 14.1. South Korea Bevacizumab Biosimilars Market Overview
• 14.2. South Korea Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Bevacizumab Biosimilars Market

• 15.1. Western Europe Bevacizumab Biosimilars Market Overview
• 15.2. Western Europe Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Bevacizumab Biosimilars Market

• 16.1. UK Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Bevacizumab Biosimilars Market

• 17.1. Germany Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Bevacizumab Biosimilars Market

• 18.1. France Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Bevacizumab Biosimilars Market

• 19.1.Italy Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2.Italy Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3.Italy Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Bevacizumab Biosimilars Market

• 20.1. Spain Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Bevacizumab Biosimilars Market

• 21.1. Eastern Europe Bevacizumab Biosimilars Market Overview
• 21.2. Eastern Europe Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Bevacizumab Biosimilars Market

• 22.1. Russia Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Bevacizumab Biosimilars Market

• 23.1. North America Bevacizumab Biosimilars Market Overview
• 23.2. North America Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Bevacizumab Biosimilars Market

• 24.1. USA Bevacizumab Biosimilars Market Overview
• 24.2. USA Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Bevacizumab Biosimilars Market

• 25.1. Canada Bevacizumab Biosimilars Market Overview
• 25.2. Canada Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Bevacizumab Biosimilars Market

• 26.1. South America Bevacizumab Biosimilars Market Overview
• 26.2. South America Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Bevacizumab Biosimilars Market

• 27.1. Brazil Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Bevacizumab Biosimilars Market

• 28.1. Middle East Bevacizumab Biosimilars Market Overview
• 28.2. Middle East Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Bevacizumab Biosimilars Market

• 29.1. Africa Bevacizumab Biosimilars Market Overview
• 29.2. Africa Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Bevacizumab Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Bevacizumab Biosimilars Market Competitive Landscape
• 30.2. Bevacizumab Biosimilars Market Company Profiles
  • 30.2.1. Cipla Limited
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Reliance lifesciences Pvt. Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Genentech Inc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Fujifilm Kyowa Kirin Biologics Co. Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Pfizer Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Bevacizumab Biosimilars Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Amgen Inc.
• 31.3. F. Hoffmann-La Roche Ltd.
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Mylan Inc.
• 31.6. Daiichi Sankyo Company Limited
• 31.7. Beaconpharma Ltd.
• 31.8. Innovent Biologics Inc.
• 31.9. STADA Arzneimittel AG
• 31.10. Shanghai Henlius Biotech Inc.
• 31.11. Aurobindo Pharma Ltd.
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Biocon Ltd.
• 31.14. Intas Pharmaceuticals Ltd.
• 31.15. Amneal Pharmaceuticals LLC

32. Global Bevacizumab Biosimilars Market Competitive Benchmarking

33. Global Bevacizumab Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Bevacizumab Biosimilars Market

35. Bevacizumab Biosimilars Market Future Outlook and Potential Analysis

• 35.1 Bevacizumab Biosimilars Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Bevacizumab Biosimilars Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Bevacizumab Biosimilars Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer